Xcout Intel
Veraxa Biotech AG
Veraxa Biotech AG discovers and develops next-generation antibody-based cancer therapeutics, including antibody-drug conjugates (ADCs) and novel antibody formats. The company utilizes proprietary technologies such as BiTAC and functional antibody screening to build a therapeutic pipeline aimed at improving patient safety and treatment efficacy.
Subscribe to see Veraxa Biotech AG’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Veraxa Biotech AG at a glance
Veraxa Biotech AG is a biotech company headquartered in Heidelberg, Germany. It is publicly listed (VRXA) with a market capitalisation of $141.4M. Xcout tracks 5 named people at Veraxa Biotech AG, including Raju Willener (Chief Financial Officer).
Veraxa Biotech AG leadership
- Raju WillenerChief Financial Officer
- Christoph ErkelChief Scientific Officer
- Heinz SchwerChief Business Officer
- Christoph AntzCo-Founder, Lead Director & CEO
- Carl von HalemPrincipal Financial Officer & Principal Accounting Officer
Recent Veraxa Biotech AG news
- IPOVeraxa Biotech Holding AG IPO on NASDAQ
Veraxa Biotech AG competitors
A few of Veraxa Biotech AG's closest competitors — see the full list of competitors and alternatives →
Cybrexa Therapeutics is a clinical-stage oncology biotechnology company that develops tumor-targeting peptide-drug conjugates (PDCs) for cancer patients. Its proprietary alphalex technology uses a pH-driven approach for antigen-independent, intracellular delivery of anti-cancer agents directly to tumors and metastases.
VAXIMM AG is a biotech company headquartered in Basel, Switzerland, that focuses on developing a new class of cytotoxic immunotherapies and clinical-stage targeted treatments through its subsidiaries.
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
AbTx (Antibody for Therapy) is a preclinical-stage biotechnology company headquartered in Dijon, France. The firm designs personalized medicine biotherapies in oncology based on antibody-drug conjugates (ADCs) to treat incurable cancers.
Philogen is a Swiss-Italian biotechnology company that focuses on the research, development, and commercialization of targeted therapeutics for the treatment of cancer and other serious conditions. The company utilizes proprietary antibody-based technologies to develop biopharmaceuticals, immunotherapies, and radio-conjugates for oncology and imaging applications.
Get Veraxa Biotech AG's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Veraxa Biotech AG? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Veraxa Biotech AG in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access